Amgen Inc. $AMGN Stake Decreased by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH trimmed its holdings in Amgen Inc. (NASDAQ:AMGN) by 21.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 463,938 shares of the medical research company’s stock after selling 129,101 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.09% of Amgen worth $129,536,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in AMGN. Nuveen LLC acquired a new position in shares of Amgen during the first quarter valued at $688,868,000. Federated Hermes Inc. increased its stake in Amgen by 48.5% during the 1st quarter. Federated Hermes Inc. now owns 2,037,169 shares of the medical research company’s stock valued at $634,680,000 after buying an additional 665,555 shares during the period. The Manufacturers Life Insurance Company raised its position in shares of Amgen by 128.9% during the 1st quarter. The Manufacturers Life Insurance Company now owns 1,065,694 shares of the medical research company’s stock worth $332,017,000 after buying an additional 600,096 shares in the last quarter. WoodTrust Financial Corp lifted its stake in shares of Amgen by 8,223.6% in the 2nd quarter. WoodTrust Financial Corp now owns 595,634 shares of the medical research company’s stock worth $166,307,000 after acquiring an additional 588,478 shares during the period. Finally, Kingstone Capital Partners Texas LLC acquired a new stake in shares of Amgen in the 2nd quarter worth approximately $156,812,000. Institutional investors own 76.50% of the company’s stock.

Amgen Trading Up 0.2%

Shares of NASDAQ AMGN opened at $336.74 on Friday. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 7.24. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $345.84. The company has a market cap of $181.33 billion, a price-to-earnings ratio of 27.53, a P/E/G ratio of 2.61 and a beta of 0.45. The business has a fifty day simple moving average of $294.91 and a 200-day simple moving average of $290.40.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, November 4th. The medical research company reported $5.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.01 by $0.63. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The firm had revenue of $9.56 billion for the quarter, compared to the consensus estimate of $8.98 billion. During the same quarter in the previous year, the company earned $5.58 EPS. The business’s revenue for the quarter was up 12.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Sell-side analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 12th. Investors of record on Friday, November 21st will be paid a $2.38 dividend. The ex-dividend date of this dividend is Friday, November 21st. This represents a $9.52 dividend on an annualized basis and a yield of 2.8%. Amgen’s dividend payout ratio (DPR) is currently 73.57%.

Insiders Place Their Bets

In other news, SVP Nancy A. Grygiel sold 1,267 shares of Amgen stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total transaction of $376,286.33. Following the transaction, the senior vice president owned 7,209 shares in the company, valued at approximately $2,141,000.91. The trade was a 14.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Murdo Gordon sold 6,879 shares of the company’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total value of $2,317,053.57. Following the transaction, the executive vice president directly owned 41,923 shares in the company, valued at $14,120,924.09. The trade was a 14.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 9,036 shares of company stock worth $2,992,594. Corporate insiders own 0.76% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. Wells Fargo & Company raised their price objective on shares of Amgen from $280.00 to $300.00 and gave the company an “overweight” rating in a research note on Wednesday, November 5th. Guggenheim lifted their price target on Amgen from $288.00 to $305.00 and gave the company a “neutral” rating in a research report on Thursday, November 6th. Deutsche Bank Aktiengesellschaft upped their price objective on Amgen from $280.00 to $285.00 and gave the company a “hold” rating in a report on Tuesday, November 11th. DZ Bank lifted their target price on Amgen from $335.00 to $364.00 in a report on Monday, November 10th. Finally, Bank of America boosted their price target on shares of Amgen from $261.00 to $272.00 and gave the stock an “underperform” rating in a research report on Friday, September 26th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $314.05.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.